类固醇治疗特发性腕管综合征的分子与临床机制解读
该研究结合体外实验和临床前瞻性观察,探讨曲安奈德治疗特发性腕管综合征的作用机制。体外实验显示曲安奈德下调纤维化相关基因Col1A1、Col1A2和Col3A1,但不影响炎症相关基因。临床MRI观察显示注射后正中神经扁平比及神经、肌腱、SSCT面积无变化,提示其疗效可能主要源于抗纤维化而非抗炎或抗水肿特性。
要点
- 曲安奈德下调纤维化基因Col1A1、Col1A2、Col3A1,不改变炎症基因表达。
- 临床MRI显示注射后正中神经扁平比及SSCT等面积无变化。
- 疗效可能主要来自抗纤维化特性,而非抗炎或抗水肿。
核心结论
- 注射曲安奈德的治疗效应似乎由抗纤维化而非抗炎和抗水肿特性介导。
- 曲安奈德可能改变SSCT的性质而非形态。
研究设计与样本
- 体外实验:术中采集特发性腕管综合征患者SSCT成纤维细胞,与或不与曲安奈德孵育1、3、7天,用qRT-PCR评估纤维化相关基因和炎症细胞因子表达。
- 临床前瞻性研究:对接受腕管曲安奈德注射的患者,在注射前及注射后1、3、5个月进行临床和电生理评估。
- 用3-T MRI比较注射前和注射后1个月的正中神经、屈肌腱、SSCT面积及正中神经扁平比。
主要发现
- 曲安奈德诱导纤维化相关基因Col1A1、Col1A2和Col3A1下调,但未下调炎症相关基因。
- MRI观察显示注射曲安奈德后正中神经扁平比未变化。
- MRI观察显示正中神经、屈肌腱和SSCT面积在注射后未报告变化。
临床怎么用
- 曲安奈德腕管注射的疗效可能主要通过抗纤维化机制实现,临床可据此理解其作用特点。
- MRI显示SSCT形态未变,提示疗效可能源于组织性质改变而非形态学变化。
局限性
- 原文未明确报告样本量、具体统计值及置信区间。
- 体外实验仅评估1、3、7天基因表达,临床影像仅比较1个月时点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Carpal tunnel steroid injection is a nonoperative intervention for the treatment for idiopathic carpal tunnel syndrome (CTS). The antifibrotic, anti-inflammatory, and antiedematous properties of steroids account for their therapeutic effects in the context of CTS; however, their relative contribution has not been clarified. METHODS: Fibroblasts from subsynovial connective tissues (SSCT) were intraoperatively collected from patients with idiopathic CTS and were incubated with or without the steroid triamcinolone acetonide (TA) for 1, 3, and 7 days; the expression of fibrosis-related genes and inflammatory cytokines was evaluated using quantitative reverse transcription-polymerase chain reaction. A clinical prospective study was conducted with patients who received carpal tunnel TA injections. We performed clinical and electrophysiological evaluations before and 1, 3, and 5 months after TA injection; and we compared the median nerve, flexor tendon, and SSCT areas and the median nerve flattening ratio before and 1 month after TA injection using 3-T magnetic resonance imaging (MRI). RESULTS: TA induced downregulation of the fibrosis-related genes Col1A1 (collagen type I alpha 1 chain), Col1A2, and Col3A1 but not the inflammation-related genes. The nerve flattening ratio did not change after TA injection according to the MRI-based observation of the median nerve, flexor tendon, and SSCT areas. CONCLUSIONS: The therapeutic effects of injected TA are apparently mediated by its antifibrotic rather than its anti-inflammatory and antiedematous properties. TA probably alters the properties but not the morphology of SSCT. LEVEL OF EVIDENCE: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.
引用
- Yamanaka Y, Tajima T, Tsujimura Y, et al. Molecular and Clinical Elucidation of the Mechanism of Action of Steroids in Idiopathic Carpal Tunnel Syndrome. J Bone Joint Surg Am. 2021. PMID: 34398862. doi:10.2106/JBJS.20.02096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。